Cite
HARVARD Citation
Vogel, A. et al. (2021). Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet gastroenterology and hepatology. pp. 649-658. [Online].